Novo Nordisk faces price war in weight loss market
Novo Nordisk reports earnings as investors weigh strong pill demand against falling prices. The firm faces new competition from Eli Lilly oral treatments.
Xurve View
洞察:
Xurve View
Novo Nordisk A/S-B is banking on high demand for its new weight-loss pill to counter a deepening price war with Eli Lilly & Co. The Denmark-based drugmaker faces pressure to prove that rising prescription volumes can offset falling margins in the obesity market. Investors are looking for a shift from defensive to offensive strategy after a $400B market value decline since a 2024 peak.
